Genetic Trickery Offers New Way to Target HIV

June 06, 1997

Scientists at the University of Rochester and UCLA have used a bit of duplicity to render human white blood cells resistant to HIV, using genetic engineering to fool the virus and disrupt its life cycle. The novel strategy is described in the June 6 issue of the Journal of Biological Chemistry.

"This turns the normal process by which HIV replicates against itself," says Joseph Rosenblatt, the lead investigator and head of Hematology/Oncology at the University of Rochester Cancer Center. "We trick the virus into shutting down its replication process prematurely."

While it's too soon to say whether the work will be clinically relevant, the scientists note that the strategy opens up a new research avenue in the gene therapy of AIDS. They have filed for a patent on the process.

To replicate itself, HIV depends on a molecule known as a tRNA primer to attach to a strand of HIV's genetic template, providing a foothold so that the enzyme reverse transcriptase can copy the viral genetic code. Initiating the copying process at precisely the right spot is the primer's critical task.

Rosenblatt's team genetically engineered a new primer, a mutant tRNA that docks at a different site on the HIV template, causing reverse transcriptase to begin copying at the wrong spot. Just like a typist whose fingers are off by one key, the result is useless -- HIV doesn't replicate, and the virus can't go on to infect more cells.

"Forcing reverse transcription to start in a different spot is a new idea," says Vicente Planelles, assistant professor at the Cancer Center, who participated in the research. "No one has previously attempted to genetically interfere with the priming process in retroviruses."

In the test tube, cells equipped with the engineered primer were infected by HIV at just one one-thousandth the normal rate of infection. The team made its measurements in cell lines of human CD4-expressing white cells, the type of helper T-cell that HIV normally attacks.

Substituting the primer with an inept impostor could be used in combination with other therapies, Rosenblatt says. Currently, protease inhibitors prevent the maturation of virus that has already infected cells, and reverse transcriptase inhibitors like AZT and Nevirapine prevent the virus from replicating within cells. The new work involves a third approach: genetically modifying a patient's cells to make them resistant to infection.

The team included scientists from the University of Rochester and UCLA. Besides Rosenblatt and Planelles, University of Rochester participants also included faculty members Robert Bambara, Pia Challita-Eid, and post-doctoral fellow Chockalingam Palaniappan. UCLA contributors included Yuanan Lu, Xinqiang Li, and Rafael Amado.

Funding for the research came from the National Institutes of Health and the Ahmanson Foundation.

University of Rochester

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to